Heart and Blood Diseases

All Conditions

Neoplasms

Symptoms and General Pathology

Blood and Lymph Conditions

Rare Diseases

Thrombosis

Neoplasm Metastasis

Polycythemia

Polycythemia Vera

Hematologic Diseases

Bone Marrow Neoplasms

Hematologic Neoplasms

Bone Marrow Diseases

Myeloproliferative Disorders

Chronic Myeloproliferative Disorders

Patients with polycythemia defined as hematocrit level greater than or equal to 49% in men and 48% in women, whatever the suspected etiology. Primitive and secondary polycythemia are eligible in this observational study. Patients should not have start any cytoreductive therapy prior inclusion.

Mael HEIBLIG, MD,PhD

Polycythemia (PG) corresponds to an increase in erythrocyte parameters on a blood test. A distinction is usually made between primary and secondary PG. The most common primary PG is Vaquez's disease, a hematological cancer. In Vaquez disease, an increase in hematocrit has been reported to be associated with a logarithmic increase in blood viscosity.

The main complications of primary PGs (especially in Vaquez disease) are thromboembolic complications. In contrast, thromboembolic complications are rarer in secondary PG. In Vaquez disease, a hematocrit ≤ 45% has been defined as the therapeutic goal for significantly reducing thromboembolic risk. However, this has not been established for secondary PGs. All in all, the definition of the 45% threshold is based solely on clinical studies with no obvious biological argument. What's more, simply lowering blood mass through cytoreduction alone does not appear to be sufficient to significantly reduce thromboembolic risk.

To investigator knowledge, there are no studies prospectively evaluating blood viscosity, its determinants and coagulation in different types of polycythemia. Nor are there any data on the direct effect on blood viscosity of the various treatments usually offered.

Blood Viscosity in Polycythemia Patients

Evaluation of Blood Viscosity and Hyperviscosity-related Complications Relationship in Patients With Patients With Polycythemia

The investigators expect higher blood viscosity values in polyglobulic patients with symptoms of clinical hyperviscosity than in polyglobulic patients without symptoms of clinical hyperviscosity, but no differences in hematocrit between the two polycythemia groups

Hospices Civils de Lyon

Nutritional and Metabolic Diseases

Diseases and Abnormalities at or Before Birth

Metabolic Diseases

Anemia

Hyperbilirubinemia

Hyperbilirubinemia, Neonatal

Anemia, Neonatal

Iron Metabolism Disorders

Neoplastic Processes

Infant, Newborn, Diseases

Micronutrients

All Drugs and Chemicals

Iron

In the ECC group, the cord was clamped immediately after delivery, before the first minute of life.

Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping

In the DCC group, the cord was clamped when it stops beating. Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping

Blood Test 6hours

Blood Test 24hours

Blood Test 48hours

Blood Test 28days

Vanesa Rodenas, PhD

This study compares two umbilical cord clamping times; the early one, up to a minute (ECC) and the late or delayed one, when the cord stop beating (DCC). The additional blood volume delivered to the newborn from the placenta - placental transference - by delaying umbilical cord ligation, increases the contribution of neonatal iron with increased iron stores in the infant, without increasing neonatal morbidity.

It is an intervention study without drugs administration with a longitudinal, prospective comparison and correlational design.

Patients are recruited by simple random sampling to one of the two intervention groups:

Group 1-ECC: Early clamping of the umbilical cord (before the first minute of life).

Group 2-DCC: Delayed clamping of the umbilical cord (when it stops beating).

Randomised controlled trials comparing early and late cord clamping

Influence of Umbilical Cord Clamping Time in the Newborn

Influence of Umbilical Cord Clamping Time in the Newborn, Secondary Neonatal Morbidity and Iron Deposits in the Neonate

Hospital Universitario de la Plana

FUNDACIÓN DAVALOS FLETCHER

Pascual Gregori Roig

Adjunct Pediatrician of University Hospital of La Plana (Spain)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Blood Viscosity in Polycythemia Patients	NCT06421025	Polycythemia Se... Polycythemia, P...		18 Years -	Hospices Civils de Lyon
Influence of Umbilical Cord Clamping Time in the Newborn	NCT03624335	Anemia Neonatal Polycythemia Se... Hyperbilirubine...	ECC DCC Blood Test 6hou... Blood Test 24ho... Blood Test 48ho... Blood Test 28da...	35 Weeks - 42 Weeks	Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Blood Viscosity in Polycythemia Patients	NCT06421025	Polycythemia Se... Polycythemia, P...		18 Years -	Hospices Civils de Lyon
Influence of Umbilical Cord Clamping Time in the Newborn	NCT03624335	Anemia Neonatal Polycythemia Se... Hyperbilirubine...	ECC DCC Blood Test 6hou... Blood Test 24ho... Blood Test 48ho... Blood Test 28da...	35 Weeks - 42 Weeks	Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Spots Global Cancer Trial Database for polycythemia secondary